Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst’s product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in [...]

- The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases - Completion of the transaction gives Angelini Pharma ownership of Catalyst’s product portfolio - The transaction is being carried out with the participation of funds managed by Blackstone - CDP Equity approves €1 billion investment in Angelini Pharma - Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), international pharmaceutical company and part of Angelini Industries, announces today the completion of its acquisition of Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX).

Catalyst is now part of Angelini Pharma, integrating Catalyst’s portfolio and commercial infrastructure with Angelini Pharma’s expertise and products in Brain Health. The transaction provides the participation of funds managed by Blackstone, that will invest 1 billion euros in preferred equity, subject to customary regulatory clearances. CDP Equity has approved to invest around 1 billion euros through a capital increase to acquire a 23.5 per cent stake in the common equity of Angelini Pharma.

The investment, strongly supported by CDP Equity, underpins Angelini Pharma’s transformation into a global player in brain health and rare diseases. It accelerates its expansion into the US market through the acquisition of Catalyst and promotes a significant increase in investments in research and development, thereby strengthening the entire national pharmaceutical sector and fostering high-quality employment growth in Italy as well. The operation was financed with the support of BNP Paribas, acting as Sole Global Coordinator and Underwriter of the overall financing package, including the bridge-to-equity, for Angelini Pharma.

Morgan Stanley & Co. International plc is acting as sole financial advisor to Angelini Pharma in connection with the participation of Blackstone and CDP Equity. This acquisition marks a pivotal moment in the ongoing transformation journey that Angelini Industries — a company with more than 100 years of history – has been pursuing with a clear strategic vision over the past four years and establishes Angelini Pharma’s presence in the U.S. as part of a balanced growth strategy, that will continue to see Italy as a strategic